News

Research by Weizmann Institute scientist and Israel Prize winner saved 'countless lives,' was basis for technology sold for ...
A University of Pennsylvania biotechnology company that aims to treat autoimmune diseases by reengineering cells within the ...
A novel chimeric antigen receptor T-cell therapy may benefit patients with B-cell lymphomas who previously relapsed following ...
While data is promising, many questions remain about topics such as timing and doses in the treatment of hematologic malignancies.
A team of researchers led by NYU Tandon School of Engineering's Weiqiang Chen has developed a miniature device that could ...
A team of physicians recently reported the successful treatment of refractory autoimmune neuropathies through the infusion of ...
During a live event, Priyanka Pophali, MD, MBBS, discussed CAR T-cell therapy referrals, timing, and challenges in relapsed ...
A Martin County family with a child fighting rare cancer is getting help from the community to get treatment abroad.
Previously, due to the risk of cytokine release syndrome and neurological toxicities, many CAR T-cell therapies included a REMS requirement.
Engineered chip mimics bone marrow and immune system, offering a faster, tailored path for cancer immunotherapy.
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $69.0, a high ...
The long-term benefits of CAR T-cell therapy, the use of residual disease activity to direct treatment, and a novel drug ...